According to Zhitong Finance APP, losses among innovative drug concept stocks widened in the afternoon session. As of press time, Ascletis Pharma-B (01672) fell 9.82% to HK$7.62; InnoCare (09969) dropped 6.37% to HK$12.65; 3SBio (01530) declined 4.20% to HK$15.04; and Innovent Bio (01801) slipped 3.90% to HK$93.7.

On the news front, a suspected plague infection incident in Russia's Irkutsk region has recently drawn international attention. WHO spokesperson Lindmeier stated on October 6 that based on currently available information, the WHO's preliminary risk assessment considers the risk in the Irkutsk region to be "moderate to low," the overall risk for the Russian Federation to be "low," and the risk for the WHO European Region to be "very low."

It is worth noting that, influenced by market expectations regarding U.S. inflation prospects and Federal Reserve rate hike expectations, the U.S. 30-year Treasury yield has recently fluctuated upward, briefly rising to 5.72% during intraday trading on October 7, approximately the highest level since 2002. As a typical "long-duration asset," innovative drugs derive their value from distant future cash flows, making their valuations highly sensitive to the discount rate (interest rates).